Alembic Pharmaceuticals gets USFDA nod for Tretinoin

Overview of the USFDA approval

Alembic Pharmaceuticals said it has received final approval from the US Food and Drug Administration (USFDA) to market Tretinoin Cream USP (0.025%) in the US. The approval is for Alembic’s abbreviated new drug application (ANDA). The product is used for topical application in the treatment of acne vulgaris. The approval adds another dermatology product to Alembic’s US generics portfolio.

For Indian pharmaceutical companies, a final ANDA approval is a key regulatory milestone because it enables commercial launch in the US, subject to the company’s readiness and market conditions. In Alembic’s case, the company is entering a segment with an established reference product and a defined prescription use case. The update was disclosed by the Vadodara-headquartered company through its regulatory communication.

What product has been approved

The approved product is Tretinoin Cream USP, 0.025%. Tretinoin is commonly prescribed for acne vulgaris and is applied topically. Alembic’s product will be positioned as a generic treatment option for the same indication.

Alembic stated that the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD). In US generic drug filings, therapeutic equivalence signals that the generic is expected to have the same clinical effect and safety profile as the reference product when used as directed.

Reference drug: Retin-A and the innovator company

Alembic said its Tretinoin Cream USP (0.025%) is the generic equivalent of Retin-A Cream 0.025%. The reference product is listed as being developed by Bausch Health US, LLC.

This linkage to the RLD matters for two reasons. First, it clarifies the exact branded benchmark used for Alembic’s ANDA pathway. Second, it places Alembic in direct competition with other generic manufacturers that may already sell equivalent tretinoin products in the US dermatology market.

Market size for Tretinoin Cream 0.025%

Alembic cited an estimated market size of US$ 94 million for Tretinoin Cream USP (0.025%). The estimate covers the twelve months ending June 2025, according to IQVIA.

While market-size estimates do not guarantee revenue, they provide a reference point for the scale of the segment Alembic is targeting. In topical dermatology, prescription volumes, payer coverage, and the number of competing generics typically influence realised pricing and market share.

How this changes Alembic’s US generics pipeline

With this approval, Alembic said it has a cumulative total of 224 ANDA approvals from the USFDA. This includes 202 final approvals and 22 tentative approvals.

The disclosure provides investors with an updated snapshot of the company’s US regulatory throughput. A larger ANDA base can help diversify product exposure across therapy areas and reduce dependence on a few molecules. But the commercial impact of any single approval typically depends on launch timing, competition, and the company’s ability to supply consistently.

Stock market reaction in India

Following the development, Alembic Pharmaceuticals shares (NSE: APLLTD) were reported to be trading at ₹991.65, up 2.05%.

Price moves on approval news are often driven by immediate expectations of a product launch and the perceived size of the addressable market. However, sustained stock performance generally depends on whether approvals translate into steady US sales and whether the company can maintain compliance and supply execution.

Manufacturing and product information disclosed

Alembic’s product information notes that Tretinoin Cream USP (0.025%) contains tretinoin USP and is used for the topical treatment of acne vulgaris. The product is associated with Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Limited, per the referenced labeling details.

The manufacturing details provided list the site as Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India, along with a License No.: G/25/2216. The label information also includes a contact line for reporting suspected adverse reactions, listing Alembic Pharmaceuticals, Inc. at 1-866-210-9797, alongside the FDA MedWatch route.

Recent USFDA approvals mentioned in the company’s broader context

The provided context also references multiple USFDA product approvals received by Alembic between 2024 and 2025. These include approvals for products such as Rivaroxaban tablets (multiple strengths) with therapeutic equivalence to Xarelto in May 2025, and Doxorubicin Hydrochloride Liposome Injection (generic version of Doxil) in June 2025.

Within this sequence, the final approval for Tretinoin Cream USP 0.025% is described as occurring in August 2025. Separately, a press release date of 15 August 2025 was provided for the Tretinoin approval announcement from Vadodara, India.

Key facts at a glance

Why the approval matters for investors tracking US launches

For Alembic, the approval expands its set of USFDA-cleared products in dermatology, a segment where chronic conditions and repeat prescriptions can support steady demand. The product’s positioning as a therapeutic equivalent to Retin-A clarifies its target use and competitive set.

At the same time, the market opportunity will depend on factors not quantified in the disclosure, such as the number of competing generics and pricing dynamics after launch. Investors typically watch for follow-up signals such as product launch announcements, distribution ramp-up, and any updates on US business performance.

Conclusion

Alembic Pharmaceuticals’ final USFDA approval for Tretinoin Cream USP (0.025%) clears the regulatory path for a US launch of its generic equivalent to Bausch Health’s Retin-A for acne vulgaris. The company also updated its US pipeline count to 224 ANDA approvals, while the stock was reported up 2.05% at ₹991.65. The next concrete milestone to track will be commercial launch execution in the US market segment that Alembic estimates at US$ 94 million for the year ended June 2025.